Immune Checkpoint Inhibitor

I recently had the pleasure of attending a symposium at the Cleveland Clinic that featured an outstanding review of immune-related adverse events, and I was reminded of how far we have come in the decade since I first became involved in the evolution of this disease class.

Use of immune checkpoint inhibitors for pregnant women with cancer may be safer than previously thought, according to study results published in JAMA Network Open.

DENVER – For older adults with MS and signs of cancer, treatment with immune checkpoint inhibitors was safe and prevented relapse or disease progression, according to interim research.

A regimen containing dostarlimab plus standard-of-care chemotherapy significantly improved OS compared with chemotherapy alone in women with primary advanced or recurrent endometrial cancer, according to the agent’s manufacturer.

Fred Hutchinson Cancer Center appointed Lawrence Fong, MD, as scientific director of the Immunotherapy Integrated Research Center.

Researchers at Salk Institute for Biological Studies have achieved promising results in early studies using an anti-CTLA-4 antibody for treatment of glioblastoma, the most common and deadliest form of brain cancer.

Immune checkpoint inhibitors may confer benefit to certain patients with advanced penile squamous cell carcinoma, according to retrospective study results.

The addition of stereotactic body radiotherapy to immune checkpoint inhibitors failed to significantly extend survival among individuals with advanced solid tumors, results of the randomized phase 2 CHEERS trial showed.

People living with HIV and various cancer types may be safely treated with immune checkpoint inhibitors, according to results of a retrospective study published in Journal of Clinical Oncology.

Incidence of venous thromboembolism remained high among patients with cancer even as the treatment landscape has evolved over the past 16 years, according to data published in JAMA Network Open.